2773 cases >0.70. The correlation between the scores of the PROSQOLI and those of the SF-12 ques- tionnaire was high (r=0.8139, p<0.0001). The ANOVA test showed signifcant differences be- tween groups (p<0.01) based on age, recurrence risk and treatment. CONCLUSIONS: The adaptation process showed that the PROSQOLI Italian version has high reliability and presents both convergent and discriminant validity. This version of the tool can be used to assess HRQoL in Italian men who underwent radical treatment for advanced pros- tate cancer. Key Words: Prostate cancer, Health-related quality of life, Patient-reported outcomes, Cross-cultural adap- tation. Introduction Prostate cancer (PCa) is one of the most com- monly diagnosed tumors representing about 20% of Abstract. – OBJECTIVE: The Prostate Cancer Specifc Quality of Life Instrument (PROSQOLI) is a measure of health-related quality of life (HRQoL) in advanced hormone-resistant pros- tate cancer. In this study, we aimed at perform- ing a cross-cultural adaptation and validation of the Italian version of the PROSQOLI. PATIENTS AND METHODS: The original ver- sion of the PROSQOLI underwent several turn- arounds of translations. A total of 472 patients treated with radical prostatectomy, radiotherapy or medical therapy were enrolled for the valida- tion of the questionnaire. The PROSQOLI was administered together with the SF-12. Reliability indexes were calculat- ed by using Cronbach alpha. To evaluate the va- lidity of the construct, relationships between PROSQOLI and SF12 were assessed. The ANOVA test was used to evaluate the dif- ferences between groups of patients who had received different treatments. RESULTS: The reliability coeffcient was 0.91. Item-to-total correlation indices were in most European Review for Medical and Pharmacological Sciences 2016; 20: 2773-2778 L. BELLARDITA 1 , R. DAMIANO 2 , F. PORPIGLIA 3 , V. SCATTONI 4 , A. AMODEO 5 , R. BORTOLUS 6 , A. LAPINI 7 , A. COCCI 7 , V. CICALESE 8 , M. CAPONERA 9 , P. MASTRANGELO 10 , F. FRANCESCA 11 , R. VALDAGNI 12 , G. TAVERNA 13 , D. DI TRAPANI 14 , R. LEONARDI 15 , D. MINOCCI 16 , F. GABOARDI 17 , E. MONTANARI 18 , G. CONTI 19 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 2 Department of Urology, Magna Graecia University of Catanzaro, Catanzaro, Italy 3 Urology, San Luigi Hospital, Regione Gonzole 10, Orbassano, Turin, Italy 4 Department of Urology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy 5 Urology, Ospedale civile di Castelfranco Veneto, Asolo, Treviso, Italy 6 Radiation Oncology Department, National Cancer Institute, Aviano, Italy 7 Department of Urology, Universital Hospital Careggi, Florence, Italy 8 Urology, Azienda Ospedaliera “S. Giuseppe Moscati”, Avellino, Italy 9 Divisione di Urologia, Ospedale Civile, Anagni, Frosinone, Italy 10 Urology Department, IRCCS-CROB, Rionero in Vulture, Potenza, Italy 11 UO Urologia II, Azienda Ospedaliero-Universitaria Pisa, University of Pisa, Pisa, Italy 12 Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 13 Department of Urology, Humanitas Mater Domini, Castellanza, Varese, Italy 14 U.O.C. di Urologia e Andrologia, Ospedale Buccheri La Ferla, Palermo, Italy 15 Urology, Centro Uro-Andrologico La Cura, Acireale, Catania, Italy 16 Urology, ASL VCO Regione Piemonte, Italy 17 Urology Department, IRCCS San Raffaele Scientific Institute, Ville Turro Division, Milan, Italy 18 Urology, San Paolo Hospital, Milan, Italy 19 Department of Urology, Sant’Anna Hospital, Como, Italy Corresponding Author: Lara Bellardita, Psy.D, Ph.D; e-mail: Lara.belladita@istitutotumori.mi.it Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI)